What the determination covers
The Health Insurance (Section 3C Co-Dependent Pathology Services) Amendment (Expanding NTRK1-3 Testing) Determination 2026 is a technical update to Medicare rules about pathology testing. It relates to testing for NTRK1-3 gene markers, which are used in cancer diagnosis, under Medicare's co-dependent pathology services arrangements.
The source page for this instrument contains only publishing and version details from the Federal Register of Legislation, not the full content of the rule changes.
Administration and status
The determination is administered by the Department of Health, Disability and Ageing under the Health Insurance Act 1973. It was registered on 12 August 2026 and shows as in force from that date to 1 November 2026.
Who this relates to
This determination primarily affects pathology providers and relates to Medicare rebate eligibility rather than general workplace obligations for small businesses.
Key actions
- Pathology or diagnostic service providers are able to check the full legislative text and explanatory statement at the Federal Register of Legislation to see if NTRK1-3 testing billing arrangements have changed.
- Businesses that bill Medicare for co-dependent pathology services can confirm with their billing software provider or practice manager whether this determination affects current claims.
This is a plain-English summary for information only, not legal or compliance advice. Always check the official source or consult a qualified professional.